Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Mak KS, et al. Among authors: dignam jj. Eur Urol Focus. 2024 Feb 1:S2405-4569(24)00011-7. doi: 10.1016/j.euf.2024.01.008. Online ahead of print. Eur Urol Focus. 2024. PMID: 38307806
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza D, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers JP, Sandler HM. Lee WR, et al. Among authors: dignam jj. J Clin Oncol. 2024 May 17:JCO2302445. doi: 10.1200/JCO.23.02445. Online ahead of print. J Clin Oncol. 2024. PMID: 38759121
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.
Xie W, Ravi P, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Clarke N, Dignam J, James N, Fizazi K, Gillessen S, Mottet N, Murphy L, Parulekar W, Sandler H, Tombal B, Williams S, Sweeney CJ. Xie W, et al. Ann Oncol. 2024 Mar;35(3):285-292. doi: 10.1016/j.annonc.2023.11.017. Epub 2023 Dec 5. Ann Oncol. 2024. PMID: 38061427
Reply by Authors.
Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. Turchan WT, et al. Among authors: dignam jj. J Urol. 2022 Jun;207(6):1245. doi: 10.1097/JU.0000000000002443.02. Epub 2022 Mar 3. J Urol. 2022. PMID: 35236091 No abstract available.
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, Hecht DP, Klute KA, Morrison VA, Pini TM, Rosner GL, Runowicz CD, Shayne M, Sparreboom A, Turner S, Zarwan C, Lyman GH. Griggs JJ, et al. Among authors: dignam jj. J Clin Oncol. 2021 Jun 20;39(18):2037-2048. doi: 10.1200/JCO.21.00471. Epub 2021 May 3. J Clin Oncol. 2021. PMID: 33939491
101 results